News – Trained Therapeutix Discovery

Trained Therapeutix Discovery’s Chief Scientific Officer, Dr. Mulder, Honored with Fellowship at the American Institute for Medical and Biological Engineering (AIMBE)

NewsBy Adrienne Hazenberg April 15, 2026

-Recognition highlights pioneering contributions to nanomedicine underpinning the company’s RIDE platform Oss, The Netherlands — April 14, 2026 — Trained Therapeutix Discovery, a biotechnology company founded by the Jean Boulle Group and the Heritage Group, today announced that its Chief Scientific Officer and scientific founder, Willem Mulder, PhD, has been inducted into the College of…

Trained Therapeutix Discovery Appoints Distinguished Industry Leaders to its Board of Directors

NewsBy Adrienne Hazenberg February 9, 2026

DALLAS and OSS, The Netherlands, Feb. 09, 2026 (GLOBE NEWSWIRE) — Trained Therapeutix Discovery, a pioneering immunotherapy biotech company revolutionizing the treatment of immune-mediated diseases through its innovative RIDE nanomedicine platform, today announced the appointment of seven distinguished industry leaders to its board of directors. This strategic enhancement positions the company to accelerate the development…

Trained Therapeutix Discovery Demonstrates RIDE-001 Trains Myeloid Cells for Anti-Tumor Immune Response in Preclinical Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

NewsBy Adrienne Hazenberg November 27, 2025

Trained Therapeutix Discovery Demonstrates RIDE-001 Trains Myeloid Cells for Anti-Tumor Immune Response in Preclinical Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting -RIDE-001, a first-in-class nanomedicine, effectively trained myeloid progenitor cells to elicit myeloid-driven anticancer innate immune responses, as demonstrated in preclinical studies across multiple species Dallas, TTxD & The Netherlands…

Trained Therapeutix Discovery Appoints Joost Kreijtz, PhD, as Chief Executive Officer of Dutch Subsidiary Trained Therapeutix Discovery (NL)

NewsBy Adrienne Hazenberg November 27, 2025

Trained Therapeutix Discovery Appoints Joost Kreijtz, PhD, as Chief Executive Officer of Dutch Subsidiary Trained Therapeutix Discovery (NL) Dallas, TX & The Netherlands — October 17, 2025 — Trained Therapeutix Discovery, Inc., a biotech company training immunity at its origin with nanomedicines, today announced that Joost Kreijtz, PhD, has been appointed Chief Executive Officer of Trained Therapeutix…

Trained Therapeutix Discovery to attend BIO-Europe in Vienna, November 3–5, 2025

NewsBy Adrienne Hazenberg November 27, 2025

Trained Therapeutix Discovery is pleased to announce its participation in BIO-Europe, taking place in Vienna from November 3 to 5, 2025. Our management team will be present and welcomes meeting requests to discuss our cutting-edge nanomedicine programs including our lead programs RIDE-001 and RIDE-002. We are open to opportunities for strategic partnerships and investments. BIO-Europe…

Dutch Minister for Medical Care Pia Dijkstra and her colleagues Karla Van Rooijen and Maarten Hazewinkel visited Pivot Park on Wednesday 15 May 2024.

NewsBy webmaster October 3, 2024

We talked with them about our company Trained Therapeutix Discovery. With platform technology from Willem Mulder and immunological insights from Mihai Netea, we develop innovative medicines for the treatment of cancer and inflammatory diseases, among others.

Trained Therapeutix Discovery appoints Nobel Laureate Dr. James Allison, Dr. Padmanee Sharma, and Dr. Mihai Netea to its Scientific Advisory Board

NewsBy webmaster April 19, 2021

Trained Therapeutix Discovery (“TTxD”) announces that it has extended its Scientific Advisory Board to include James P. Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. Dr. Allison received the 2018 Nobel Prize in Physiology or Medicine for his work on discovering immune checkpoint blockade and is the Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. Dr. Sharma is a pioneer and world-renowned expert in designing and running immuno-oncology clinical trials and is a practicing immunologist and oncologist at MD Anderson Cancer Center.

Trained Therapeutix Discovery Inc. Appoints Dr. Willem Mulder as Chief Scientific Officer – Expert in Use of Nanomaterials as Immunotherapeutics, Former Professor at Icahn School of Medicine at Mount Sinai, and Professor at Eindhoven University of Technology and Radboud University Medical Center

NewsBy webmaster January 5, 2021

Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Therapeutics, announces the appointment of Prof. Dr. Willem Mulder as Chief Scientific Officer effective 1 January 2021.

Trained Therapeutix Discovery Inc.’s Exclusively Licensed Technology Shown to Suppress Cancer Growth

NewsBy webmaster November 2, 2020

Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Therapeutics, notes the results of a preclinical Study (“the Study”) published in Cell showing how nanobiologic immunotherapy promotes trained immunity and elicits a durable anti-tumor response either as a monotherapy or in combination with other checkpoint inhibitor drugs.

Landmark trial shows trained immunity reduces respiratory infections in the elderly by 80%

NewsBy webmaster September 1, 2020

Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Therapeutics, notes the results of a clinical trial¹ (“the Trial”) published in Cell showing that trained immunity through the use of BCG vaccination can reduce respiratory tract infections by 80% amongst elderly people including, potentially, COVID-19.

Category Archives: News